Los Angeles Capital Management LLC Fate Therapeutics Inc Transaction History

Los Angeles Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	SELL	$9.86 - $23.83 $14,937 - $36,102	-1,515 Reduced 8.05%	17,313 $174,000
Q3 2022 Nov 02, 2022	BUY	$21.04 - $36.06 $26,236 - $44,966	1,247 Added 7.09%	18,828 $422,000
Q2 2022 Aug 05, 2022	BUY	$17.78 - $42.39 $10,685 - $25,476	601 Added 3.54%	17,581 $436,000
Q1 2022 May 06, 2022	SELL	$29.67 - $60.28 $22,163 - $45,029	-747 Reduced 4.21%	16,980 $658,000
Q4 2021 Feb 03, 2022	BUY	$47.84 - $64.34 $6,793 - $9,136	142 Added 0.81%	17,727 $1.04 Million
Q2 2021 Aug 05, 2021	SELL	$67.25 - $92.52 $119,705 - $164,685	-1,780 Reduced 9.19%	17,585 $1.53 Million
Q1 2021 May 05, 2021	SELL	$72.16 - $117.4 $825,005 - $1.34 Million	-11,433 Reduced 37.12%	19,365 $1.6 Million
Q4 2020 Feb 04, 2021	BUY	$38.09 - $100.95 $12,950 - $34,323	340 Added 1.12%	30,798 $2.8 Million
Q3 2020 Nov 02, 2020	BUY	$30.41 - $40.5 $41,813 - $55,687	1,375 Added 4.73%	30,458 $1.22 Million
Q2 2020 Aug 05, 2020	BUY	$20.21 - $35.23 $72,574 - $126,510	3,591 Added 14.09%	29,083 $997,000
Q1 2020 May 04, 2020	BUY	$17.28 - $31.88 $440,501 - $812,684	25,492 New	25,492 $566,000

167

108M

79.2K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $138M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.